![Da Jan Yang](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Da Jan Yang
Directeur Général chez
ASCENTAGE PHARMA GROUP INTERNATIONAL
Profil
Dajun Yang was the founder of Ascenta Therapeutics, Inc. (California), founded in 2004, serving as GM, Director & SVP-Research & Preclinical from 2005 to 2008.
Dr. Yang is the founder of Ascentage Pharma Group International Co., Ltd., founded in 2009, holding the position of Chairman & Chief Executive Officer since 2017.
Current jobs include Chairman & Chief Executive Officer at Suzhou Ascentage Pharma Co. Ltd., and Director roles at Ascentage Pharma Group, Inc., Ascentage Pharma Pty Ltd., Ascentage International Ltd., Shanghai Yasheng Pharmaceutical Technology Co. Ltd., and Ascentage Pharma Group Corp.
Ltd. Former jobs include Vice President-Biology at S*BIO Pte Ltd. from 2002 to 2003, Member-Supervisory Board & Professor at Sun Yat-Sen University from 2003 to 2006, and President of The Chinese Biopharmaceutical Association from 2005 to 2006.
Education history includes a doctorate from Michigan State University conferred in 1992, a graduate degree from Sun Yat-Sen University conferred in 1986, and an undergraduate degree from Sun Yat-Sen University conferred in 1983.
Postes actifs de Da Jan Yang
| Sociétés | Poste | Début |
|---|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Directeur Général | 01/05/2009 |
Ascentage Pharma Group Corp. Ltd.
 Ascentage Pharma Group Corp. Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Directeur/Membre du Conseil | - |
Ascentage International Ltd. | Directeur/Membre du Conseil | - |
Shanghai Yasheng Pharmaceutical Technology Co., Ltd. | Directeur/Membre du Conseil | - |
Ascentage Pharma Group, Inc.
 Ascentage Pharma Group, Inc. Pharmaceuticals: OtherHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group, Inc. is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule and degrader therapies primarily targeting hematologic malignancies and select solid tumors. Ascentage maintains rights to its key assets and has established partnerships with pharmaceutical companies including Takeda, Innovent, AstraZeneca, Merck, and Pfizer, as well as collaborations with research institutions such as Dana-Farber, Mayo Clinic, MD Anderson, and the National Cancer Institute. The company is based in Rockville, MD. The company leverages expertise in structure-based drug design and proprietary platforms to focus on restoring apoptosis and inhibiting oncogenic signaling pathways by targeting proteins such as bcl-2, bcl-xl, iap, mdm2-p53, and tyrosine kinases including bcr-abl1, alk, fak, and ros1. Its lead approved products include olverembatinib, a third-generation bcr-abl1 tyrosine kinase inhibitor for treatment-resistant chronic myeloid leukemia, and lisaftoclax, a novel oral bcl-2 inhibitor for chronic lymphocytic leukemia/small lymphocytic lymphoma after prior therapies. Both drugs are included in the national reimbursement drug list and are undergoing multiple phase III registrational trials cleared by regulatory agencies such as the FDA and EMA. The clinical pipeline also features pelcitoclax, a dual bcl-2/bcl-xl inhibitor for small cell lung cancer; alrizomadlin, an mdm2-p53 inhibitor; apg-2449, a fak/alk/ros1 inhibitor for non-small-cell lung cancer; and apg-3288, a novel btk degrader. The company is conducting over 40 international clinical trials across hematologic malignancies and solid tumors, emphasizing monotherapy and combination regimens. | Directeur/Membre du Conseil | - |
Jiangsu Ascentage Pharma Pty Ltd. | Directeur/Membre du Conseil | - |
Ascentage Pharma Suzhou Co Ltd
 Ascentage Pharma Suzhou Co Ltd Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Directeur Général | - |
Anciens postes connus de Da Jan Yang
| Sociétés | Poste | Fin |
|---|---|---|
Ascenta Therapeutics, Inc. (California) | Directeur Général | 01/01/2008 |
Sun Yat-Sen University
 Sun Yat-Sen University Other Consumer ServicesConsumer Services Functions as a College/University | Directeur/Membre du Conseil | 01/09/2006 |
| ░░░ ░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Da Jan Yang
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
97
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
Ascenta Therapeutics, Inc. (California) | |
Michigan State University
 Michigan State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers novel targeted small molecule drugs | Health Technology |
Sun Yat-Sen University
Sun Yat-Sen University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Chinese Biopharmaceutical Association | |
Ascentage Pharma Group International Co., Ltd.
 Ascentage Pharma Group International Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in discovering, developing and commercializing of therapies for hematological malignancies | Health Technology |
Ascentage Pharma Group, Inc.
Ascentage Pharma Group, Inc. Pharmaceuticals: OtherHealth Technology Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group, Inc. is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule and degrader therapies primarily targeting hematologic malignancies and select solid tumors. Ascentage maintains rights to its key assets and has established partnerships with pharmaceutical companies including Takeda, Innovent, AstraZeneca, Merck, and Pfizer, as well as collaborations with research institutions such as Dana-Farber, Mayo Clinic, MD Anderson, and the National Cancer Institute. The company is based in Rockville, MD. The company leverages expertise in structure-based drug design and proprietary platforms to focus on restoring apoptosis and inhibiting oncogenic signaling pathways by targeting proteins such as bcl-2, bcl-xl, iap, mdm2-p53, and tyrosine kinases including bcr-abl1, alk, fak, and ros1. Its lead approved products include olverembatinib, a third-generation bcr-abl1 tyrosine kinase inhibitor for treatment-resistant chronic myeloid leukemia, and lisaftoclax, a novel oral bcl-2 inhibitor for chronic lymphocytic leukemia/small lymphocytic lymphoma after prior therapies. Both drugs are included in the national reimbursement drug list and are undergoing multiple phase III registrational trials cleared by regulatory agencies such as the FDA and EMA. The clinical pipeline also features pelcitoclax, a dual bcl-2/bcl-xl inhibitor for small cell lung cancer; alrizomadlin, an mdm2-p53 inhibitor; apg-2449, a fak/alk/ros1 inhibitor for non-small-cell lung cancer; and apg-3288, a novel btk degrader. The company is conducting over 40 international clinical trials across hematologic malignancies and solid tumors, emphasizing monotherapy and combination regimens. | Health Technology |
Jiangsu Ascentage Pharma Pty Ltd. | |
Ascentage International Ltd. | |
Shanghai Yasheng Pharmaceutical Technology Co., Ltd. | |
Ascentage Pharma Suzhou Co Ltd
Ascentage Pharma Suzhou Co Ltd Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Ascentage Pharma Group Corp. Ltd.
Ascentage Pharma Group Corp. Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Choisissez Zonebourse 
